Hologic Showcases Newest Mammography Technology at RSNA 2013

November 22, 2013 — Hologic Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products with an emphasis on serving the healthcare needs of women, announced the imaging products it will highlight at the Radiological Society of North America Annual Meeting (RSNA 2013) Dec. 1-5 in Chicago.

 

Hologic is dedicating a significant share of its RSNA exhibit to the clinical benefits of 3-D mammography in breast cancer screening and diagnosis as well as its recently introduced lower-dose 3-D mammography and 3-D guided breast biopsy capabilities.

 

The C-View 2-D software option is designed to generate a 2-D image from a 3-D mammography data set without the need for separate 2-D X-ray exposures. C-View software is designed to offer radiologists and patients a number of benefits, including a reduction in X-ray exposures leading to shorter exam times (less than four second scans per view) and increased patient comfort from the shorter compression time. Hologic’s 3-D mammography exam using C-View software is a lower dose mammogram than the average U.S. 2-D mammogram, and yet it includes all the benefits of a combined 2-D and 3-D mammography exam.

 

The Affirm 3-D mammography biopsy option is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2-D imaging or when using other modalities. This new biopsy technique is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. The Affirm system is preprogrammed for use with the Company's Eviva and ATEC vacuum-assisted breast biopsy devices. 

 

The Selenia Dimensions 3-D mammography system is currently the only U.S. Food and Drug Administration (FDA)-approved 3-D system in the United States, and Hologic is the only company worldwide that can provide a 3-D breast biopsy solution.

 

The 3-D mobile coach is making a special stop at RSNA on its yearlong, cross-country “3-D Technology: A More Accurate Mammogram” tour, which is dedicated to spreading the word about the important clinical benefits of 3-D mammography. 

Additionally, over 60 new scientific papers, poster sessions and sponsored courses will be presented at RSNA on 3-D mammography, many of which used Hologic’s 3-D technology. 

 

 

For more information: www.hologic.com, www.rsna.org